Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Celldex Therapeutics, Inc. (NASDAQ: CLDX).

Full DD Report for CLDX

You must become a subscriber to view this report.


Recent News from (NASDAQ: CLDX)

Celldex Announces Presentations at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
HAMPTON, N.J., May 16, 2018 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that two abstracts will be presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting being held June 1-5, 2018 in Chicago. The schedule for the presentations i...
Source: GlobeNewswire
Date: May, 16 2018 17:01
Celldex Trying To Regroup With Its Early-Stage Assets
It was clear back in April that Celldex Therapeutics ( CLDX ) would be restructuring and realigning its priorities after the failure of its Phase III METRIC study of glembatumumab ("glemba") in triple-negative breast cancer, and after the first quarter earnings report, investors have a clear...
Source: SeekingAlpha
Date: May, 11 2018 11:59
Celldex misses by $0.64, beats on revenue
Celldex (NASDAQ: CLDX ): Q1 EPS of -$0.84 misses by $0.64 . More news on: Celldex Therapeutics, Inc, Earnings news and commentary, Stocks on the move, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: May, 10 2018 08:12
Celldex Provides Corporate Update and Reports First Quarter 2018 Results
HAMPTON, N.J., May 10, 2018 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the first quarter ended March 31, 2018. “Celldex has made considerable progress on an important strategic prioritization of our pipeline, f...
Source: GlobeNewswire
Date: May, 10 2018 08:00
Biotech Analysis Central Pharma News: Takeda Raises Shire Bid, Daiichi Fails DMD Trial, Celldex Cuts 20% Of Workforce
Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. Takeda Raises Its Bid For Shire To $64 Billion News: Recently, Takeda (TKPPY) raised its bid so that it could acquire Shire ( SHPG ). The latest ...
Source: SeekingAlpha
Date: April, 26 2018 15:22
Data from Multiple Celldex Programs Presented at American Association for Cancer Research (AACR) Annual Meeting 2018
-- Early data from investigator-initiated pilot study of CDX-301/radiation therapy combination in patients with advanced NSCLC show promising effect on tumor burden even in non-irradiated tumors -- -- Additional four posters at AACR Annual Meeting support ongoing Phase 2 study of CDX-...
Source: GlobeNewswire
Date: April, 20 2018 08:01
Analysis: Positioning to Benefit within Celldex Therapeutics, McDermott International, Briggs & Stratton, Tile Shop Hldgs, Essendant, and Anworth Mortgage Asset - Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK, April 20, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Celldex Therapeutics, Inc. (NASDAQ:CLDX), McDermott International, Inc. ...
Source: GlobeNewswire
Date: April, 20 2018 07:55
Celldex Nearly Back To Square One
Once again Celldex ( CLDX ) shareholders have had to come to terms with a major disappointment. Following the spring 2016 announcement that the company’s lead drug Rintega had failed in Phase III, Celldex announced earlier this week that its pivotal METRIC study of glembatumu...
Source: SeekingAlpha
Date: April, 19 2018 10:46
3 Things In Biotech, April 18: Bristol Plows Ahead, Celldex Flops, Alkermes Gets A Surprise
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Click here to read more about what you get from me. Welcome to another edition of "3 Things In Biotech," a daily digest dedica...
Source: SeekingAlpha
Date: April, 19 2018 08:00
OncoSec: The Underlying Science Of ImmunoPulse Powers A Potential Winner
Even in those earlier times, finding the really outstanding companies and staying with them through all the fluctuations of a gyrating market proved far more profitable to far more people than did the more colorful practice of trying to buy them cheap and sell them dear. - The Father of Growt...
Source: SeekingAlpha
Date: April, 18 2018 13:54

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-130.430.41940.43230.4105642,322
2018-08-090.4810.44990.4810.4411,304,461
2018-08-080.4680.4640.470.44983,195
2018-08-070.43510.44530.460.4221,028,931
2018-08-060.440.42550.44360.4131900,733

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-1361,933195,07031.7491Cover
2018-08-10278,144554,01750.2050Short
2018-08-09169,742358,90847.2940Short
2018-08-08274,506347,19279.0646Short
2018-08-07173,105335,54351.5895Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on CLDX.


About Celldex Therapeutics, Inc. (NASDAQ: CLDX)

Logo for Celldex Therapeutics, Inc. (NASDAQ: CLDX)

Not available

 

Contact Information

 

 

Current Management

  • Una S. Ryan / President, CEO, COO
  • Avery W. Catlin / CFO, Secretary

Current Share Structure

  • Market Cap: $99,541,580 - 05/15/2018
  • Issue and Outstanding: 141,073,668 - 02/28/2018

 


Recent Filings from (NASDAQ: CLDX)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 10 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: May, 10 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 10 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 30 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 24 2018
Filing Type: CT ORDERFiling Source: edgar
Filing Date: April, 20 2018
Preliminary proxy statement providing notification matters to be brought to a vote
Filing Type: PRE 14AFiling Source: edgar
Filing Date: April, 19 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 16 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 07 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 07 2018

 

 


Daily Technical Chart for (NASDAQ: CLDX)

Daily Technical Chart for (NASDAQ: CLDX)


Stay tuned for daily updates and more on (NASDAQ: CLDX)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: CLDX)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in CLDX is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of CLDX and does not buy, sell, or trade any shares of CLDX. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/